4.7 Review

Fishing anti(lymph)angiogenic drugs with zebrafish

Journal

DRUG DISCOVERY TODAY
Volume 23, Issue 2, Pages 366-374

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2017.10.018

Keywords

-

Funding

  1. Spanish Ministry of Economy and Competitiveness [BIO2014-56092-R]
  2. FEDER [BIO2014-56092-R, BIO-267]
  3. PIE [P12-CTS-1507, CVI-6585]
  4. Andalucian Government [BIO-267]

Ask authors/readers for more resources

Zebrafish, an amenable small teleost fish with a complex mammal-like circulatory system, is being increasingly used for drug screening and toxicity studies. It combines the biological complexity of in vivo models with a higher-throughput screening capability compared with other available animal models. Externally growing, transparent embryos, displaying well-defined blood and lymphatic vessels, allow the inexpensive, rapid, and automatable evaluation of drug candidates that are able to inhibit neovascularisation. Here, we briefly review zebrafish as a model for the screening of anti(lymph) angiogenic drugs, with emphasis on the advantages and limitations of the different zebrafish-based in vivo assays.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available